Functional and clinical importance of SGLT2-inhibitors in frailty: From the kidney to the heart
SGLT2 (sodium-glucose cotransporter 2) enables glucose and sodium reabsorption in the
kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin …
kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin …
Frailty and heart failure: State‐of‐the‐art review
At least half of all patients with heart failure (HF) are affected by frailty, a syndrome that limits
an individual ability to recover from acute stressors. While frailty affects up to 90% of patients …
an individual ability to recover from acute stressors. While frailty affects up to 90% of patients …
Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial
Background: Frailty is increasing in prevalence. Because patients with frailty are often
perceived to have a less favorable risk/benefit profile, they may be less likely to receive new …
perceived to have a less favorable risk/benefit profile, they may be less likely to receive new …
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association …
Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous
clinical syndrome affected in its development and progression by many comorbidities. The …
clinical syndrome affected in its development and progression by many comorbidities. The …
Comparative cardiovascular effectiveness and safety of SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors according to frailty in type 2 diabetes
A Kutz, DH Kim, DJ Wexler, J Liu… - Diabetes …, 2023 - Am Diabetes Assoc
OBJECTIVE To evaluate the comparative cardiovascular effectiveness and safety of sodium–
glucose cotransporter 2 inhibitors (SGLT-2is), glucagon-like peptide 1 receptor agonists …
glucose cotransporter 2 inhibitors (SGLT-2is), glucagon-like peptide 1 receptor agonists …
Sacubitril/valsartan and frailty in patients with heart failure and preserved ejection fraction
Background Frailty is an increasingly common problem, and frail patients are less likely to
receive new pharmacologic therapies because the risk–benefit profile is perceived to be …
receive new pharmacologic therapies because the risk–benefit profile is perceived to be …
The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus
M Evans, AR Morgan, S Davies, H Beba… - Age and …, 2022 - academic.oup.com
Abstract Sodium-glucose co-transporter-2 (SGLT2) inhibitors offer significant outcome
benefits beyond glucose lowering, including reduced risk of cardiovascular death, all-cause …
benefits beyond glucose lowering, including reduced risk of cardiovascular death, all-cause …
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
Type 2 diabetes mellitus (T2DM) is a highly prevalent health condition in the aging
population. Older adults with T2DM have higher risks of cardiovascular disease, heart failure …
population. Older adults with T2DM have higher risks of cardiovascular disease, heart failure …
Efficacy and safety of dapagliflozin in patients with chronic kidney disease across the spectrum of frailty
Background A sizeable proportion of patients with chronic kidney disease (CKD) are
reported to be frail. Here we examined the safety and efficacy of dapagliflozin in patients …
reported to be frail. Here we examined the safety and efficacy of dapagliflozin in patients …
Frailty status modifies the efficacy of ICD therapy for primary prevention among patients with HF
Background Implantable cardioverter-defibrillator (ICD) therapy is recommended to reduce
mortality risk in patients with heart failure with reduced ejection fraction (HFrEF). Frailty is …
mortality risk in patients with heart failure with reduced ejection fraction (HFrEF). Frailty is …